Oppenheimer Maintains Market Outperform on Avadel Pharmaceuticals, Raises Price Target to $25
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Francois Brisebois maintains a Market Outperform rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raises the price target from $22 to $25.
June 30, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained a Market Outperform rating on Avadel Pharmaceuticals and raised the price target from $22 to $25.
The news of Oppenheimer maintaining a Market Outperform rating and raising the price target for Avadel Pharmaceuticals is likely to instill confidence in investors and could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100